Tofacitinib in Children with Ulcerative Colitis (Pfizer OVATION Protocol A3921210)

IRB
CHLA-21-00016
OPEN-LABEL INDUCTION AND MAINTENANCE STUDY OF ORAL CP-690,550 (TOFACITINIB) IN CHILDREN WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

To evaluate the efficacy of tofacitinib based on remission in pediatric participants with moderately to severely active Ulcerative Colitis (UC).

Study Details
Clinical Trials Government Identifier
NCT04624230
Keywords
tofacitnib UC, ulcerative colitis, cp-690, 550
Eligibility

1.) Males and Females between the ages of 2 and 17 years old
2.) UC diagnosis, moderate to severely active UC as defined by Mayo Score and PUCAI
3.) An inadequate response to TNF inhibitors
4.) No history of TB, colectomy, or certain UC treatments
Does this study also recruit healthy volunteers?
No
Enrollment Status
Open